Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate

Trial Profile

Efficacy and safety of nilotinib in patients with chronic graft versus host disease (GVHD) who did not respond to imatinib mesylate

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nilotinib (Primary) ; Imatinib
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms Double-ITK-GVHc
  • Most Recent Events

    • 09 Jul 2019 Status changed from active, no longer recruiting to completed.
    • 07 Jul 2018 This trial has been completed in France, according to European Clinical Trials Database.
    • 19 Jun 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top